Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Cerebral deposition of the beta-amyloid peptide (A beta) is an invariant feature of Alzheimer's disease. Since the original isolation and characterization of A beta (ref. 1) and the subsequent cloning of its precursor protein, no direct evidence for the actual production of discrete A beta has been reported. Here we investigate whether A beta is present in human biological fluids using antibodies specific for an epitope within A beta that spans the site of normal constitutive cleavage. These antibodies were used to construct a sandwich-type enzyme-linked immunosorbent assay that detects A beta in cerebrospinal fluid, plasma and conditioned medium of human mixed-brain cells grown in vitro (see also ref. 14). By affinity chromatography, we have purified and sequenced A beta and a novel A beta fragment from human cerebrospinal fluid and conditioned medium of human mixed-brain cell cultures. These findings demonstrate that A beta is produced and released both in vivo and in vitro. These observations offer new opportunities for developing diagnostic tests for Alzheimer's disease and therapeutic strategies aimed at reducing the cerebral deposition of A beta.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“studies that shed light on the physiological role of Aβ in non-diseased brains show that Aβ plays a role in synaptic transmission and is involved in learning and memory formation [18–22].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [18]
In the citing paper
“Recently, we and others have shown that normal processing of the large amyloid f3 protein precursor ({3-APP) secretes 4-kDa A(3 that is readily detected in human cerebrospinal fluid and in medium conditioned by cultured cells (3)(4)(5)(6).”
From Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain (1995) · cites this paper as [3]
In the citing paper
“The demonstration that A-related peptides with the same N terminals as the CTFs documented here are present in conditioned medium of cultured cells (Seubert et al., 1992;Naslund et al., 1994;Simons et al., 1996;Wang et al., 1996;Xu et al., 1998)”
From Alzheimer Amyloid Protein Precursor in the Rat Hippocampus: Transport and Processing through the Perforant Path (1998) · cites this paper as Seubert et al., 1992
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCleavage of Amyloid β Peptide During Constitutive Processing of Its Precursor
Esch, F. S., Keim, P. S., Beattie, E. C., Blacher, R. W., Culwell, A. R., Oltersdorf, T., McClure, D., & Ward, P. J. (1990) · Science · doi:10.1126/science.2111583 · Cited by 1,410
Self-citationMutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type
Levy, E., Carman, M. D., Fernandez-Madrid, I. J., Power, M. D., Lieberburg, I., van Duinen, S. G., Bots, G. T. A. M., Luyendijk, W., & Frangione, B. (1990) · Science · doi:10.1126/science.2111584 · Cited by 1,381
Self-citationChartier-Harlin, M.-C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., Goate, A., Rossor, M., Roques, P., Hardy, J., et al. (1991) · Nature · doi:10.1038/353844a0 · Cited by 1,214
A mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease
Murrell, J., Farlow, M., Ghetti, B., & Benson, M. D. (1991) · Science · doi:10.1126/science.1925564 · Cited by 1,127
Tanzi, R. E., McClatchey, A. I., Lamperti, E. D., Villa-Komaroff, L., Gusella, J. F., & Neve, R. L. (1988) · Nature · doi:10.1038/331528a0 · Cited by 1,096
Cited by
Items 601–700 of 1,726
α2β1 and αVβ1 integrin signaling pathways mediate amyloid-β-induced neurotoxicity
Wright, S., Malinin, N. L., Powell, K. A., Yednock, T. A., Rydel, R. E., & Griswold‐Prenner, I. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.12.002 · Cited by 79
Ginsenoside Rg3 promotes beta-amyloid peptide degradation by enhancing gene expression of neprilysin
Yang, L., Hao, J., Zhang, J., Xia, W., Dong, X., Hu, X., Kong, F., & Cui, X. (2009) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.61.03.0013 · Cited by 78
“Ab, a physiological peptide, is constantly anabolized and catabolized in the brain,([4]) and the steady-state Ab levels are determined by the metabolic balance between anabolic and catabolic activity.”
BackgroundSasahara, K., Morigaki, K., & Shinya, K. (2013) · Physical Chemistry Chemical Physics · doi:10.1039/c3cp44517h · Cited by 89
Amyloid precursor protein secretion and βA4 amyloid generation are not mutually exclusive
Dyrks, T., Mönning, U., Beyreuther, K., & Turner, J. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00671-7 · Cited by 75
Aspects of β-Amyloid as a Biomarker for Alzheimer's Disease
Andreasson, U., Portelius, E., Andersson, M. E., Blennow, K., & Zetterberg, H. (2007) · Biomarkers in Medicine · doi:10.2217/17520363.1.1.59 · Cited by 74
Rygiel, K. (2016) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.194867 · Cited by 73
“[6] Products of this reaction include two forms of the amyloid beta peptide: (1) A chain containing 40 amino acids (the main form), and (2) a chain containing 42 amino acids (amyloid beta 1–42).[7] The amyloid beta 1–42 is more prone to aggregate into fibrils, which are the main components of cerebral neurotoxic senil…”
BackgroundRed cell perturbations by amyloid β-protein
Rajadas, J., Kusiak, J. W., Chrest, F. J., Demehin, A. A., Jayaraman, M., Wersto, R. P., Nagababu, E., Ravi, L. B., & Rifkind, J. M. (2003) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(03)00101-6 · Cited by 77
Chen, F., Yang, D.-S., Petanceska, S., Yang, A., Tandon, A., Yu, G., Rozmahel, R., Ghiso, J., Nishimura, M., Zhang, D. M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006986200 · Cited by 75
Davis-Salinas, J., & Van Nostrand, W. E. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.36.20887 · Cited by 74
Extracellular Matrix Influences the Biogenesis of Amyloid Precursor Protein in Microglial Cells
Mönning, U., Banati, R. B., Masters, C. L., Sandbrink, R., Weidemann, A., & Beyreuther, K. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7104 · Cited by 74
Amyloid plaques in cerebellar cortex and the integrity of Purkinje cell dendrites
Li, Y.-T., Woodruff‐Pak, D. S., & Trojanowski, J. Q. (1994) · Neurobiology of Aging · doi:10.1016/0197-4580(94)90139-2 · Cited by 78
Multhaup, G. (1994) · Biochimie · doi:10.1016/0300-9084(94)90163-5 · Cited by 89
Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features
Giaccone, G., Morbin, M., Moda, F., Botta, M., Mazzoleni, G., Uggetti, A., Catania, M., Moro, M. L., Redaelli, V., Spagnoli, A., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0747-1 · Cited by 73
“Accordingly, and despite the preponderance of Ab40 in physiologic conditions, that represents about 90% of the Ab species in human CSF as well as in conditioned media of APP expressing cells, the major constituent of SP is Ab42, suggesting that its aggregation plays a critical role in the process of amyloid formation…”
BackgroundOxidative stress induces macroautophagy of amyloid β-protein and ensuing apoptosis
Zheng, L. P., Kågedal, K., Dehvari, N., Benedikz, E., Cowburn, R. F., Marcusson, J. O., & Terman, A. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.10.043 · Cited by 85
β‐secretase as a target for the treatment of Alzheimer's disease
Citron, M. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10393 · Cited by 81
“cells that express amyloid precursor protein (APP) and it can be measured in the brain, plasma and cerebrospinal fluid (CSF) of animals and patients (Haass et al., 1992; Seubert et al., 1992; Shoji et al., 1992).”
BackgroundInfluentialCapillary electrophoresis studies on the aggregation process of β‐amyloid 1‐42 and 1‐40 peptides
Sabella, S., Quaglia, M., Lanni, C., Racchi, M., Govoni, S. M., Caccialanza, G., Calligaro, A., Bellotti, V., & Lorenzi, E. D. (2004) · Electrophoresis · doi:10.1002/elps.200406062 · Cited by 82
Wisniewski, H. M., Fragkowiak, J., Zoltowska, A., & Kim, K. S. (1994) · Amyloid · doi:10.3109/13506129409148619 · Cited by 73
Mollenhauer, B., Parnetti, L., Rektorová, I., Kramberger, M. G., Pikkarainen, M., Schulz‐Schaeffer, W., Aarsland, D., Svenningsson, P., Farotti, L., Verbeek, M. M., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13390 · Cited by 80
“While both t-tau and a-syn release into the CSF and interstitial fluid are thought to at least partially reflect injury to the neuronal plasma membrane, several metabolites of the amyloid precursor protein (APP) including Ab42 are constitutively secreted under physiological conditions (Haass et al. 1992; Seubert et al…”
BackgroundDementia: Alzheimer pathology and vascular factors: From mutually exclusive to interaction
van Norden, A. G. W., van Dijk, E. J., de Laat, K. F., Scheltens, P., Olde-Rikkert, M. G. M., & de Leeuw, F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.07.003 · Cited by 88
Membrane dynamics, cholesterol homeostasis, and Alzheimer's disease
Chauhan, N. B. (2003) · Journal of Lipid Research · doi:10.1194/jlr.r300010-jlr200 · Cited by 64
“mal physiological conditions, indicating that all fragments of APP, including A peptide, are part of normal physiology (53, 54).”
BackgroundBitting, L., Naidu, A., Cordell, B., & Murphy, G. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.27.16084 · Cited by 72
Yamaguchi, H., Ishiguro, K., Sugihara, S., Nakazato, Y., Kawarabayashi, T., Sun, X., & Hirai, S. (1994) · Acta Neuropathologica · doi:10.1007/bf00389492 · Cited by 51
“cultured cells [3, 8, 28], and soluble A13 is present in the cerebrospinal fluid [26, 28].”
Zhong, P., Gu, Z., Wang, X., Jiang, H., Feng, J., & Yan, Z. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302789200 · Cited by 71
Apolipoprotein C-III is an Amyloid-β-Binding Protein and an Early Marker for Alzheimer's Disease
Shih, Y.-H., Tsai, K.-J., Lee, C.-W., Shiesh, S.-C., Chen, W.-T., Pai, M.-C., & Kuo, Y.-M. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140111 · Cited by 70
Zhu, Z., Li, C., Wang, X., Yang, Z., Chen, J., Hu, L., Jiang, H., & Shen, X. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06751.x · Cited by 74
“2,2¢,4¢-Trihydroxychalcone reduced Ab plaque formation in mice Excessive Ab accumulation in the form of senile plaque is confirmed to be a major cause for AD-related degeneration in hippocampus and cerebral cortex that play pivotal roles in learning and memory-formation (Seubert et al. 1992; Hardy 1997; Selkoe and Wol…”
BackgroundMc Donald, J. M., O'Malley, T. T., Liu, W., Mably, A. J., Brinkmalm, G., Portelius, E., Wittbold, W. M., Frosch, M. P., & Walsh, D. M. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.01.005 · Cited by 72
“07/1 Monoclonal Truncated Ab that starts with pyroglutamate – 2 mg/ml – Probiodrug/[32] 6E10 Monoclonal Residues 6–10 of Ab – 1 mg/ml – Signet/[33] 266 Monoclonal Residues 16–23 of Ab – 1 mg/ml 3 mg/ml Elan/[34] 4G8 Monoclonal Residues 17–24 of Ab – 1 mg/ml – Signet/[35]”
BackgroundModulation of Aβ 42 fìbrillogenesis by glycosaminoglycan structure
Valle‐Delgado, J. J., Alfonso‐Prieto, M., de Groot, N. S., Ventura, S., Samitier, J., Rovira, C., & Fernàndez‐Busquets, X. (2010) · The FASEB Journal · doi:10.1096/fj.09-153551 · Cited by 77
“A 42 was incubated in excess of polysaccharide or PVS (peptide to polysaccharide or PVS ratio of 1:22, w/w) in an attempt to simulate the conditions in the brain extracellular medium, where GAGs are in a higher concentration than A (29, 55).”
MethodZinc and Health: Current Status and Future Directions
Hambidge, M. (2000) · Cited by 86
Protein Phosphorylation and APP Metabolism
Silva, E. F. D. C. E., & Silva, O. A. B. D. C. E. (2003) · Neurochemical Research · doi:10.1023/a:1025630627319 · Cited by 76
“The A� peptides produced are generally A� 1‐40 or A� 1‐42 (69, 70 ), although several other peptides may be generated because of heterogeneity in the � -secretase cleavage (Fig. 4). In the nonamyloidogenic pathway, � -secretase cleaves within the A� fragment (at Lys 16 ), thus precluding A� formation (Fig. 4). Subsequ…”
The possible place of cathepsins and cystatins in the puzzle of Alzheimer disease: A review
Bernstein, H., Kirschke, H., Wiederanders, B., Kh, P., Zipress, A., & Rinne, A. (1996) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815106 · Cited by 74
Quantification of Alzheimer Amyloid β Peptides Ending at Residues 40 and 42 by Novel ELISA Systems
Jensen, M., Hartmann, T., Engvall, B., Wang, R., Uljon, S. N., Sennvik, K., Näslund, J., Muehlhauser, F., Nordstedt, C., Beyreuther, K., et al. (2000) · Molecular Medicine · doi:10.1007/bf03401938 · Cited by 70
Tsuzuki, K., Fukatsu, R., Yamaguchi, H., Tateno, M., Imai, K., Fujii, N., & Yamauchi, T. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00834-x · Cited by 82
Ikura, K., Takahata, K., & Sasaki, R. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)81772-r · Cited by 77
Therapeutic applications of ribozymes
Kijima, H. (1995) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(95)02008-x · Cited by 72
Martel, C. L., Mackic, J. B., McComb, J. G., Ghiso, J., & Zlokovic, B. V. (1996) · Neuroscience Letters · doi:10.1016/s0304-3940(96)12462-9 · Cited by 69
Hydroxyquinoline based binders: Promising ligands for chelatotherapy?
Budimir, A., Humbert, N., Elhabiri, M., Nierengarten, I., Biruš, M., & Albrecht‐Gary, A. (2010) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2010.08.014 · Cited by 72
Lipids in Amyloid-β Processing, Aggregation, and Toxicity
Morgado, I., & Garvey, M. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-17344-3_3 · Cited by 71
Fukuchi, K., Ho, L., Younkin, S. G., Kunkel, D. D., Ogburn, C. E., LeBoeuf, R. C., Furlong, C. E., Deeb, S. S., Nochlin, D., Węgiel, J., et al. (1996) · Europe PMC (PubMed Central) · Cited by 77
Emerging Alzheimer’s disease therapies: inhibition of β-secretase
Citron, M. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00122-7 · Cited by 74
Lichtenthaler, S. F., Beher, D., Grimm, H. S., Wang, R., Shearman, M. S., Masters, C. L., & Beyreuther, K. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.032395699 · Cited by 69
Paik, S. R., Lee, J.-H., Kim, D.-H., Chang, C.-S., & Kim, Y.-S. (1998) · FEBS Letters · doi:10.1016/s0014-5793(97)01537-8 · Cited by 69
Aβ deposition inhibitor screen using synthetic amyloid
Esler, W. P., Stimson, E. R., Ghilardi, J. R., Felix, A. M., Lu, Y., Vinters, H. V., Mantyh, P. W., & Maggio, J. E. (1997) · Nature Biotechnology · doi:10.1038/nbt0397-258 · Cited by 85
Interfacially Polymerized Particles with Heterostructured Nanopores for Glycopeptide Separation
Song, Y., Li, X., Fan, J., Kang, H., Zhang, X., Chen, C., Liang, X., & Wang, S. (2018) · Advanced Materials · doi:10.1002/adma.201803299 · Cited by 71
Chang, Y., & Chen, Y. (2014) · The FEBS Journal · doi:10.1111/febs.12813 · Cited by 69
Interaction between amyloid β‐protein aggregates and membranes
Kakio, A., Yano, Y., Takai, D., Kuroda, Y., Matsumoto, O., Kozutsumi, Y., & Matsuzaki, K. (2004) · Journal of Peptide Science · doi:10.1002/psc.570 · Cited by 68
“For example, Aβ has been shown spontaneously to form amyloid fibrils upon incubation of Aβ solution at 37 °C, but the concentration required for this (>10−4 –10−5 M) [4–6] is much higher than the physiological concentration of Aβ in biological fluids (<10−8 M) [7].”
BackgroundA cellular complex of BACE1 and γ-secretase sequentially generates Aβ from its full-length precursor
Liu, L., Ding, L., Rovere, M., Wolfe, M. S., & Selkoe, D. J. (2019) · Journal of Cell Biology · doi:10.1083/jcb.201806205 · Cited by 64
“The discovery of the normal cellular production of Aβ via an apparent intramembrane cleavage of APP (Haass et al., 1992; Seubert et al., 1992; Shoji et al., 1992) provided the first evidence of the unusual hydrolysis of peptide bonds within the lipid bilayer, and the parallel discovery of the intramembrane cleavage of…”
BackgroundSelf-citationAβ(25–35) and Aβ(1–40) act on different calcium channels in CA1 hippocampal neurons
Rovira, C., Arbez, N., & Mariani, J. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02072-7 · Cited by 71
Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure
Vorobyeva, A. G., & Saunders, A. J. (2018) · Cilia · doi:10.1186/s13630-018-0059-y · Cited by 67
Rational Design of β-Sheet Ligands Against Aβ42-Induced Toxicity
Hochdörffer, K., März‐Berberich, J., Nagel‐Steger, L., Epple, M., Meyer‐Zaika, W., Horn, A. H. C., Sticht, H., Sinha, S., Bitan, G., & Schrader, T. H. (2011) · Journal of the American Chemical Society · doi:10.1021/ja107675n · Cited by 70
Self-citationCurrò, M., Risitano, R., Ferlazzo, N., Cirmi, S., Gangemi, C. M. A., Caccamo, D., Ientile, R., & Navarra, M. (2016) · Scientific Reports · doi:10.1038/srep20809 · Cited by 74
β-Amyloid (1–42) peptide impairs blood-brain barrier function after intracarotid infusion in rats
Jancsó, G., Domoki, F., Sántha, P., Varga, J., Fischer, J., Orosz, K., Penke, B., Becskei, A., Dux, M., & Tóth, L. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00622-3 · Cited by 68
CSF beta-amyloid, cognition, and APOE genotype in Alzheimer’s disease
Samuels, S. C., Silverman, J. M., Marin, D. B., Peskind, E. R., Younki, S. G., Greenberg, D. A., Schnur, E., Santoro, J., & Davis, K. L. (1999) · Neurology · doi:10.1212/wnl.52.3.547 · Cited by 67
Thinakaran, G., & Sisodia, S. S. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31761-1 · Cited by 67
In search of γ-secretase: Presenilin at the cutting edge
Selkoe, D. J., & Wolfe, M. S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.11.5690 · Cited by 66
Self-citationInvolvement of free oxygen radicals in β-amyloidosis: An hypothesis
Friedlich, A. L., & Butcher, L. L. (1994) · Neurobiology of Aging · doi:10.1016/0197-4580(94)90076-0 · Cited by 75
Selective Secretase Targeting for Alzheimer’s Disease Therapy
Miranda, A., Montiel, E., Ulrich, H., & Paz, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201027 · Cited by 66
Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse
Seubert, P., Barbour, R., Khan, K., Motter, R., Tang, P., Kholodenko, D., Kling, K., Schenk, D., Johnson-Wood, K., Schroeter, S., et al. (2008) · Neurodegenerative Diseases · doi:10.1159/000112834 · Cited by 66
“In parallel, exons encoding mouse Ck (accession No. V01569) and Cg2a (accession No. J00470) were cloned by PCR amplification of the respective gene segments using mouse genomic DNA as template and primers flanking the gene segments in the 5′ intron and 3′ untranslated regions of the respective genes. Following sequenc…”
MethodSelf-citationPeptidomic analyses: The progress in enrichment and identification of endogenous peptides
Peng, J., Zhang, H., Niu, H., & Wu, R. (2020) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2020.115835 · Cited by 75
Perivascular spaces as a potential biomarker of Alzheimer’s disease
Lynch, M., Pham, W., Sinclair, B., O'Brien, T. J., Law, M., & Vivash, L. E. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1021131 · Cited by 71
“Amyloid-β is a commonly synthesized and secreted protein (Seubert et al., 1992); however, in AD, two primary oligomers become dominant, Aβ40 and Aβ42.”
BackgroundAlzheimer’s disease biomarkers and their current use in clinical research and practice
Hunter, T., Santos, L. E., Tovar-Moll, F. F., & Felice, F. G. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02709-z · Cited by 88
Controlling β-Amyloid Oligomerization by the Use of Naphthalene Sulfonates
Gonzales, A. D. F., Robbs, B. K., Moreau, V. H., Ferreira, A., Juliano, L., Valente, A. P., Almeida, F. C. L., Silva, J. L., & Foguel, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501651200 · Cited by 73
Elimova, E. C., Kisilevsky, R., Szarek, W. A., & Ancsin, J. B. (2004) · The FASEB Journal · doi:10.1096/fj.03-1436fje · Cited by 70
Gkanatsiou, E., Portelius, E., Toomey, C. E., Blennow, K., Zetterberg, H., Lashley, T., & Brinkmalm, G. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.02.033 · Cited by 69
Mechanisms of Cerebrovascular Amyloid Deposition: Lessons from Mouse Models
BURGERMEISTER, P., CALHOUN, M. E., WINKLER, D. T., & JUCKER, M. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06381.x · Cited by 66
Buée, L., Ding, W., Anderson, J. P., Narindrasorasak, S., Kisilevsky, R., Boyle, N. J., Robakis, N. K. R. K., Delacourte, A., Greenberg, B., & Fillit, H. M. (1993) · Brain Research · doi:10.1016/0006-8993(93)90321-d · Cited by 66
Ho, L., Fukuchi, K.-I., & Younkin, S. G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.48.30929 · Cited by 66
Amyloid β 1-42 deposits do not lead to Alzheimer's neuritic plaques in aged dogs
WISNIEWSKI, T., LALOWSKI, M., BOBIK, M., RUSSELL, M., STROSZNAJDER, J., & FRANGIONE, B. (1996) · Biochemical Journal · doi:10.1042/bj3130575 · Cited by 65
The Isolation and Characterization of a Novel Corticostatin/Defensin-like Peptide from the Kidney
Bateman, A., Macleod, J., Lembessis, P., Hu, J., Esch, F. S., & Solomon, S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.18.10654 · Cited by 72
Self-citationFrautschy, S. A., Horn, D. L., Sigel, J. J., Harris-White, M. E., Mendoza, J. J., Yang, F., Saido, T. C., & Cole, G. M. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-20-08311.1998 · Cited by 65
“, 1992) and is found in normal CSF (Seubert et al., 1992).”
BackgroundPyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy
Perez-Garmendia, R., & Gevorkian, G. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311050004 · Cited by 65
“The main A variants detected in the human brain are A 1-40 and A 1-42, however a significant proportion of AD brain A consists also of N-terminal truncated species (A n40/42 where n=2 to 11) [1, 11-22].”
BackgroundBandyopadhyay, S., Hartley, D. M., Cahill, C. M., Lahiri, D. K., Chattopadhyay, N., & Rogers, J. T. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20864 · Cited by 63
“Levels of Ab-peptide were measured (in 96-well plates) using the standard sandwich ELISA assay that used 2G3 and 21F12 as capture antibodies for Ab-40 and Ab42 assays respectively (Seubert et al., 1992; Johnson et al., 1997; Baulac et al., 2003), and 266B antibody was used for detection.”
MethodWang, Y., MacDonald, R. G., Thinakaran, G., & Kar, S. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9849-7 · Cited by 70
Dugan, J. M., deWit, C., McConlogue, L., & Maltese, W. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.18.10982 · Cited by 66
Amyloid-β binds catalase with high affinity and inhibits hydrogen peroxide breakdown
Milton, N. G. N. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3440293 · Cited by 65
Amyloid and Alzheimer's Disease: Inside and Out
Tam, J. H. K., & Pasternak, S. H. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100013408 · Cited by 66
Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers
Mankhong, S., Kim, S., Lee, S., Kwak, H., Park, D., Joa, K., & Kang, J. (2022) · Biomedicines · doi:10.3390/biomedicines10040850 · Cited by 81
Papassotiropoulos, A., Lambert, J.-C., Wavrant-De Vrièze, F., Wollmer, M. A., von der Kammer, H., Streffer, J. R., Maddalena, A., Huynh, K.-D., Wolleb, S., Lütjohann, D., et al. (2005) · Neurodegenerative Diseases · doi:10.1159/000090362 · Cited by 51
“By combining the information of genome scans with a novel candidate gene approach that is based upon specific information on gene expression levels in the brain, we found evidence that CH25H is expressed differentially in brains of patients with AD, and that genetic variants in the vicinity of this gene are associated…”
McConlogue, L., Castellano, F., deWit, C., Schenk, D., & Maltese, W. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.3.1343 · Cited by 65
Self-citationBrazil, M. I., Chung, H., & Maxfield, F. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000937200 · Cited by 65
Frenkel, D., Balass, M., Katchalski‐Katzir, E., & Solomon, B. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00003-x · Cited by 68
Rasmussen, L. K., Sørensen, E. S., Petersen, T. E., Gliemann, J., & Jensen, P. H. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)80356-0 · Cited by 72
Matheou, C. J., Younan, N. D., & Viles, J. H. (2015) · Biochemical Journal · doi:10.1042/bj20141168 · Cited by 64
Surface Roughness Modulates Diffusion and Fibrillation of Amyloid-β Peptide
Shezad, K., Zhang, K., Hussain, M., Dong, H., He, C., Gong, X., Xie, X., Zhu, J., & Shen, L. (2016) · Langmuir · doi:10.1021/acs.langmuir.6b01756 · Cited by 72
Hashimoto, Y., Kaneko, Y., Tsukamoto, E., Frankowski, H., Kouyama, K., Kita, Y., Niikura, T., Aiso, S., Bredesen, D. E., Matsuoka, M., et al. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02513.x · Cited by 63
“Ab concentrationins in plasma as well as in the cerebrospinal fluid of AD patients have been speculated to be much less than the micromolar level (Seubert et al. 1992; Shoji et al. 1992).”
BackgroundHarman, D. (1993) · AGE · doi:10.1007/bf02436127 · Cited by 65
“The amyloid present in the amyloid core is probably formed in part in the course of normal metabolism ( 78- 80 ); endocytosis of APP followed by lysosomal processing and subsequent secretion of a number of breakdown products, including amyloidgenic and potentially amyloidgenic forms (81, 82) in the same manner as for…”
BackgroundAnti-amyloidogenic, anti-oxidant and anti-apoptotic role of gelsolin in Alzheimer’s disease
Chauhan, V. P. S., Ji, L., & Chauhan, A. (2008) · Biogerontology · doi:10.1007/s10522-008-9169-z · Cited by 69
Anderson, J. J., Höltz, G., Baskin, P. P., Wang, R., Mazzarelli, L., Wagner, S. L., & Menzaghi, F. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00244-4 · Cited by 76
Barritt, J. D., & Viles, J. H. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.684084 · Cited by 67
“These secretases, which have variable site specificity for APP, produce different lengths of A , reviewed by Kummer and Heneka (3).”
BackgroundInfluentialReviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer
Spies, P. (2012) · Frontiers in Bioscience · doi:10.2741/4035 · Cited by 60
“(9, 10) It was thereafter repeatedly shown”
Kuperstein, F., & Yavin, E. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02056.x · Cited by 67
“A soluble amyloid beta (Ab) peptide can be detected in normal plasma, cerebrospinal ¯uid and brain tissue, and is also secreted by cultured cells (Seubert et al., 1992; Tabaton et al., 1994).”
BackgroundCarboxy terminal of β-amyloid deposits in aged human, canine, and polar bear brains
Tekirian, T. L., Cole, G. M., Russell, M. J., Yang, F., Weikstein, D. R., Patel, E., Snowdon, D. A., Markesbery, W. R., & Geddes, J. W. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(95)02062-4 · Cited by 69
Manelli, A. M., & Puttfarcken, P. S. (1995) · Brain Research Bulletin · doi:10.1016/0361-9230(95)02034-x · Cited by 68
Sambamurti, K., Greig, N. H., Utsuki, T., Barnwell, E. L., Sharma, E., Mazell, C., Bhat, N. R., Kindy, M. S., Lahiri, D. K., & Pappolla, M. A. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07213.x · Cited by 62
“The Ab and Aa fragments predominantly end at residue 40, whereas other forms, including Ab42 are present at much lower levels (Seubert et al. 1992; Cai et al. 1993).”
BackgroundMilton, N. G. N. (2001) · NeuroToxicology · doi:10.1016/s0161-813x(01)00064-x · Cited by 69
Cui, J., Wang, J., Zheng, M., Gou, D., Liu, C., & Zhou, Y. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.07.021 · Cited by 62
Impact of aging immune system on neurodegeneration and potential immunotherapies
Liang, Z., Zhao, Y., Ruan, L., Zhu, L., Jin, K., Zhuge, Q., Su, D., & Zhao, Y. L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.07.006 · Cited by 67
“What is encouraging is the emergence the Solanezumab which is a conformation-specific antibody that solely recognizes soluble Ab and monomeric Ab but not Ab plaque (Racke et al., 2005; Sengupta et al., 2016; Seubert et al., 1992).”
Amyloid β-peptide induces cholinergic dysfunction and cognitive deficits: a minireview
Tran, M. H., Yamada, K., & Nabeshima, T. (2002) · Peptides · doi:10.1016/s0196-9781(02)00062-1 · Cited by 66
Petanceska, S. S., Burke, S., Watson, S. J., & Devi, L. A. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90190-2 · Cited by 68
Castillo, G. M., Lukito, W., Peskind, E., Raskind, M., Kirschner, D. A., Yee, A. G., & Snow, A. D. (2000) · Journal of Neuroscience Research · doi:10.1002/1097-4547(20001101)62:3<451::aid-jnr15>3.0.co;2-f · Cited by 60
Bharadwaj, P., Solomon, T., Malajczuk, C. J., Mancera, R. L., Howard, M. J., Arrigan, D. W. M., Newsholme, P., & Martins, R. N. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.03.015 · Cited by 66
Metadata
- Authors
- Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., McCormack, R., Wolfert, R., Selkoe, D., Lieberburg, I., & Schenk, D.
- Affiliations
- Austrian Academy of Sciences (AT)
- Venue
- Nature
- Published
- 1992-09
- Volume
- 359
- Issue
- 6393
- Pages
- 325-327
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2086278983
- Cited by
- 1,731
- References
- 28
- Citations by year
- 2026: 4 · 2025: 14 · 2024: 32 · 2023: 19 · 2022: 22 · 2021: 31 · 2020: 28 · 2019: 25 · 2018: 35 · 2017: 39 · 2016: 31 · 2015: 48 · 2014: 46 · 2013: 39 · 2012: 50
- FWCI
- 72.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, cerebrospinal fluid, plasma, conditioned medium, sandwich ELISA, affinity chromatography, epitope-specific antibodies, amyloid deposition, diagnostic biomarkers
- MeSH terms
- Alzheimer Disease, Amino Acid Sequence, Antibodies, Monoclonal, Brain, Cells, Cultured, Cross Reactions, Enzyme-Linked Immunosorbent Assay, Humans, Molecular Sequence Data, Peptide Fragments, Radioimmunoassay, Solubility, Amyloid beta-Peptides, Amyloid beta-Protein Precursor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.